Quick Answer
Enveric Biosciences, Inc. reported Research And Development Expense of $2.78 million for the year ending 2025.
- Enveric Biosciences, Inc. showed a decrease of -2.1% in Research And Development Expense from 2024 to 2025.
- This data is from Enveric Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 27, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2010: $0.00 | Q2 2011: $0.00 | Q2 2020: $51.0 thousand | Q3 2020: $63.3 thousand | Q1 2021: $158.0 thousand | Q2 2021: $879.8 thousand | Q3 2021: $1.22 million | Q1 2022: $1.96 million | Q2 2022: $2.12 million | Q3 2022: $2.06 million | Q1 2023: $1.83 million | Q2 2023: $2.40 million | Q3 2023: $1.28 million | Q1 2024: $506.2 thousand | Q2 2024: $565.0 thousand | Q3 2024: $802.7 thousand | Q1 2025: $746.4 thousand | Q2 2025: $1.26 million | Q3 2025: $402.4 thousand.
- Over the full 6 years of available data (2020 to 2025), Enveric Biosciences, Inc.'s Research And Development Expense has grown by 1,497.5%.
- Historical annual values: Fiscal year 2025: $2.78 million | Fiscal year 2024: $2.84 million | Fiscal year 2023: $7.25 million | Fiscal year 2022: $8.03 million | Fiscal year 2021: $4.79 million | Fiscal year 2020: $174.1 thousand.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: